Potenciális mielóma multiplex ellenes vegyületek szintézise és vizsgálata

Translated title of the contribution: Synthesis and investigation of potent CDK9 inhibitors with antiproliferative effect in multiple myeloma cell lines

Czudor Zsófia, Bánhegyi Péter, Boros Sándor, Breza Nóra, Fábián Márk, Szántai Kis Csaba, Markó Péter, Sipos Anna, Szokol Bálint, L. Őrfi

Research output: Contribution to journalArticle

Abstract

We have planned and synthesized a focused molecule library against myeloma multiplex. Their antiproliferative efficiency was tested on RPMI-8226 myeloma multiplex cell line. The most active compounds have micromolar IC50 value. Based on literature data presumable the role of CDK9 enzyme in the development of myeloma multiplex, therefore we have examined the CDK9 inhibitory activity of our compounds. The nanomolar IC50 values have confirmed our hypothesis. We determined our compounds inhibitory activity against other cyclin-dependent kinases (CDK2, CDK7) and we found the compounds selective on the CDK9 enzyme.

Original languageHungarian
Pages (from-to)47-57
Number of pages11
JournalActa Pharmaceutica Hungarica
Volume88
Issue number2
Publication statusPublished - Jan 1 2018

Fingerprint

Multiple Myeloma
Inhibitory Concentration 50
Cell Line
Cyclin-Dependent Kinases
Enzymes
Libraries

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Zsófia, C., Péter, B., Sándor, B., Nóra, B., Márk, F., Csaba, S. K., ... Őrfi, L. (2018). Potenciális mielóma multiplex ellenes vegyületek szintézise és vizsgálata. Acta Pharmaceutica Hungarica, 88(2), 47-57.

Potenciális mielóma multiplex ellenes vegyületek szintézise és vizsgálata. / Zsófia, Czudor; Péter, Bánhegyi; Sándor, Boros; Nóra, Breza; Márk, Fábián; Csaba, Szántai Kis; Péter, Markó; Anna, Sipos; Bálint, Szokol; Őrfi, L.

In: Acta Pharmaceutica Hungarica, Vol. 88, No. 2, 01.01.2018, p. 47-57.

Research output: Contribution to journalArticle

Zsófia, C, Péter, B, Sándor, B, Nóra, B, Márk, F, Csaba, SK, Péter, M, Anna, S, Bálint, S & Őrfi, L 2018, 'Potenciális mielóma multiplex ellenes vegyületek szintézise és vizsgálata', Acta Pharmaceutica Hungarica, vol. 88, no. 2, pp. 47-57.
Zsófia C, Péter B, Sándor B, Nóra B, Márk F, Csaba SK et al. Potenciális mielóma multiplex ellenes vegyületek szintézise és vizsgálata. Acta Pharmaceutica Hungarica. 2018 Jan 1;88(2):47-57.
Zsófia, Czudor ; Péter, Bánhegyi ; Sándor, Boros ; Nóra, Breza ; Márk, Fábián ; Csaba, Szántai Kis ; Péter, Markó ; Anna, Sipos ; Bálint, Szokol ; Őrfi, L. / Potenciális mielóma multiplex ellenes vegyületek szintézise és vizsgálata. In: Acta Pharmaceutica Hungarica. 2018 ; Vol. 88, No. 2. pp. 47-57.
@article{f29ee060b5684652be71bd94d9c2f012,
title = "Potenci{\'a}lis miel{\'o}ma multiplex ellenes vegy{\"u}letek szint{\'e}zise {\'e}s vizsg{\'a}lata",
abstract = "We have planned and synthesized a focused molecule library against myeloma multiplex. Their antiproliferative efficiency was tested on RPMI-8226 myeloma multiplex cell line. The most active compounds have micromolar IC50 value. Based on literature data presumable the role of CDK9 enzyme in the development of myeloma multiplex, therefore we have examined the CDK9 inhibitory activity of our compounds. The nanomolar IC50 values have confirmed our hypothesis. We determined our compounds inhibitory activity against other cyclin-dependent kinases (CDK2, CDK7) and we found the compounds selective on the CDK9 enzyme.",
keywords = "Cyclin-dependent kinase 9, Muliple myeloma, Pyrimidine derivatives",
author = "Czudor Zs{\'o}fia and B{\'a}nhegyi P{\'e}ter and Boros S{\'a}ndor and Breza N{\'o}ra and F{\'a}bi{\'a}n M{\'a}rk and Csaba, {Sz{\'a}ntai Kis} and Mark{\'o} P{\'e}ter and Sipos Anna and Szokol B{\'a}lint and L. Őrfi",
year = "2018",
month = "1",
day = "1",
language = "Hungarian",
volume = "88",
pages = "47--57",
journal = "Acta Pharmaceutica Hungarica",
issn = "0001-6659",
publisher = "Magyar Gyogyszereszeti Tarsasag",
number = "2",

}

TY - JOUR

T1 - Potenciális mielóma multiplex ellenes vegyületek szintézise és vizsgálata

AU - Zsófia, Czudor

AU - Péter, Bánhegyi

AU - Sándor, Boros

AU - Nóra, Breza

AU - Márk, Fábián

AU - Csaba, Szántai Kis

AU - Péter, Markó

AU - Anna, Sipos

AU - Bálint, Szokol

AU - Őrfi, L.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - We have planned and synthesized a focused molecule library against myeloma multiplex. Their antiproliferative efficiency was tested on RPMI-8226 myeloma multiplex cell line. The most active compounds have micromolar IC50 value. Based on literature data presumable the role of CDK9 enzyme in the development of myeloma multiplex, therefore we have examined the CDK9 inhibitory activity of our compounds. The nanomolar IC50 values have confirmed our hypothesis. We determined our compounds inhibitory activity against other cyclin-dependent kinases (CDK2, CDK7) and we found the compounds selective on the CDK9 enzyme.

AB - We have planned and synthesized a focused molecule library against myeloma multiplex. Their antiproliferative efficiency was tested on RPMI-8226 myeloma multiplex cell line. The most active compounds have micromolar IC50 value. Based on literature data presumable the role of CDK9 enzyme in the development of myeloma multiplex, therefore we have examined the CDK9 inhibitory activity of our compounds. The nanomolar IC50 values have confirmed our hypothesis. We determined our compounds inhibitory activity against other cyclin-dependent kinases (CDK2, CDK7) and we found the compounds selective on the CDK9 enzyme.

KW - Cyclin-dependent kinase 9

KW - Muliple myeloma

KW - Pyrimidine derivatives

UR - http://www.scopus.com/inward/record.url?scp=85051443789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051443789&partnerID=8YFLogxK

M3 - Article

VL - 88

SP - 47

EP - 57

JO - Acta Pharmaceutica Hungarica

JF - Acta Pharmaceutica Hungarica

SN - 0001-6659

IS - 2

ER -